The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | Applying molecular understanding of DLBCL to management strategies
Andrew Davies MRCP, PhD, University of Southampton, Southampton, UK outlines the utility of molecular profiling for the classification of diffuse large B-cell lymphoma (DLBCL) subtypes and subsequently, how this can be applied in treatment as therapeutic targeting of specific oncogenic abberations.This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
